We had our oncology appointment today to go over Paul’s latest scan results and discuss what comes next.
The positive news is that there’s no evidence of progression, and the bone scan has shown significant improvement. The suspected new lesion has also been ruled out, which is a huge relief.
However, Paul’s PSA is continuing to rise, which suggests that something is happening somewhere, even if it’s not yet visible on scans. Because of this, the oncologist feels he may be becoming castrate resistant. Not the news we were hoping for, especially when we are only 8 months into this journey.
The plan for now is to continue with Abiraterone for the next 3 months, with further scans scheduled for the end of May. If those scans show progression, the next step will likely be a new treatment combination as part of the TALAPRO-3 approach (Enzalutamide + Talazoparib), which has shown promising results in men with a similar diagnosis to Paul.
Chemotherapy is still being kept as an option for later.
The oncologist also really emphasised how important it is for Paul to stay as fit and healthy as possible, as future treatments may be more demanding.
So, while this isn’t the update we’d hoped for, we do have a clear plan moving forward.
Next chapter begins… one step at a time.
Whatever cancer throws your way, we’re right there with you.
We’re here to provide physical, financial and emotional support.
© Macmillan Cancer Support 2026 © Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). Also operating in Northern Ireland. A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 3rd Floor, Bronze Building, The Forge, 105 Sumner Street, London, SE1 9HZ. VAT no: 668265007